Salvage therapy in patients with advanced non-small cell lung cancer
| Autor: | Pablo M, Bedano, Nasser H, Hanna |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male Salvage Therapy Lung Neoplasms Dose-Response Relationship Drug Maximum Tolerated Dose Docetaxel Middle Aged Prognosis Survival Analysis Erlotinib Hydrochloride Clinical Trials Phase III as Topic Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols Quinazolines Humans Female Neoplasm Invasiveness Taxoids Aged Neoplasm Staging Randomized Controlled Trials as Topic |
| Zdroj: | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 1(6) |
| ISSN: | 1556-1380 |
| Popis: | Patients with advanced non-small cell lung cancer continue to have a poor prognosis; most die from the disease within 1 year. Chemotherapy is beneficial for some patients in the first-line metastatic setting. Three agents, namely docetaxel, pemetrexed, and erlotinib, are approved by the United States Food and Drug Administration as treatment in the second-line setting. In this article, we examine the data supporting the use of these agents in the second-line setting and review data from other completed trials. Lastly, we propose strategies to advance the treatment of patients with non-small cell lung cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|